Number of asthma-associated complications and healthcare service engagements reported from 12 months before commencing IL-5 inhibitor treatment to 18 months of IL-5 inhibitor treatment
| Mean | % nil exacerbation | P value | OR | CI | |
| Exacerbation—hospitalisation | |||||
| Baseline (n=230) | 1.42 | 52% (n=121) | |||
| 6 months (n=191) | 0.21 | 84% (n=160) | Baseline–6 months p<0.001 | 0.15 | 0.10 to 0.20 |
| 12 months (n=135) | 0.28 | 82% (n=110) | Baseline–12 months p<0.001 | 0.21 | 0.15 to 0.30 |
| 18 months (n=97) | 0.34 | 80% (n=78) | Baseline–18 months p<0.001 | 0.27 | 0.18 to 0.38 |
| Exacerbation—community treated | |||||
| Baseline (n=230) | 1.09 | 65% (n=149) | |||
| 6 months (n=191) | 0.16 | 89% (n=169) | Baseline–6 months p<0.001 | 0.14 | 0.10 to 0.21 |
| 12 months (n=135) | 0.24 | 85% (n=115) | Baseline–12 months p<0.001 | 0.21 | 0.14 to 0.30 |
| 18 months (n=97) | 0.24 | 86% (n=83) | Baseline–18 months p<0.001 | 0.22 | 0.14 to 0.35 |
| Oral corticosteroid use | |||||
| Baseline (n=153) | 6.81 mg | 6% (n=9) | |||
| 6 months (n=153) | 0.24 mg | 81% (n=125) | Baseline–6 months p<0.001 | 0.11 | 0.09 to 0.14 |
| 12 months (n=135) | 0.36 mg | 78% (n=105) | Baseline–12 months p<0.001 | 0.22 | 0.18 to 0.26 |
| 18 months (n=97) | 0.40 mg | 77% (n=75) | Baseline–18 months p<0.001 | 0.28 | 0.23 to 0.34 |
| GP visits | Six or less visits | ||||
| Baseline (n=230) | 6.68 | 58% (n=133) | |||
| 6 months (n=191) | 0.83 | 99% (n=190) | Baseline–6 months p<0.001 | 0.03 | 0.025 to 0.045 |
| 12 months (n=135) | 1.16 | 96% (n=129) | Baseline–12 months p<0.001 | 0.05 | 0.04 to 0.07 |
| 18 months (n=97) | 2.16 | 94% (n=8) | Baseline–18 months p<0.001 | 0.06 | 0.04 to 0.08 |
Baseline = number of reported events in the 12 months prior to starting IL-5 treatment.
Exacerbation = increase in asthma symptoms requiring oral corticosteroid treatment/increase in maintenance oral corticosteroid dose for management.
Exacerbation—hospitalisation = number of recorded exacerbations requiring inpatient hospital treatment of at least 1 day.
Exacerbation—non-inpatient = recorded exacerbations requiring specialist respiratory review but not requiring inpatient management.
Oral corticosteroid = average number of courses of oral corticosteroid/increase in maintenance oral corticosteroid dose prescribed for treatment of asthma symptoms.
GP visit = recorded visits to General Practitioner for respiratory-associate symptoms.
Mean = average number of events per patient over the started time period.
% nil exacerbation = the percentage of patients in each analysis who reported no exacerbations over the stated time period.
n = total number of patients included in each analysis.
P value = significance measure of change in results over the stated time period.
6 months = total number of events recorded in the 6 months following commencement of IL-5 inhibitor treatment. 12 months = total number of events recorded in the 12 months following commencement of IL-5 inhibitor treatment. 18 months = total number of events recorded in the 18 months following commencement of IL-5 inhibitor treatment.